$BFYW
Better For You Wellness, Inc. Stock $bfyw

$bfyw Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000157587223000924 Filed on June 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2023
Revenue	$1.850K	$2.410K	$11.41K
YoY Change	-85.87%	58.55%
Cost Of Revenue	$930.00	$3.030K	$18.41K
YoY Change	-90.94%	315.07%	2421.78%
Gross Profit	$920.00	-$620.00	-$6.995K
YoY Change	-67.38%	-178.48%	-985.44%
Gross Profit Margin	49.73%	-25.73%	-61.28%
Selling, General & Admin	$705.0K	$1.151M	$1.215M
YoY Change	-6.87%	110.53%	-25.66%
% of Gross Profit	76631.52%
Research & Development	$0.00		$0.00
YoY Change
% of Gross Profit	0.0%
Depreciation & Amortization	$190.00	$200.00	$776.00
YoY Change	0.0%
% of Gross Profit	20.65%
Operating Expenses	$705.0K	$1.151M	$3.336M
YoY Change	-6.87%	138.89%	104.15%
Operating Profit	-$704.1K	-$1.152M	-$3.343M
YoY Change	-6.64%	139.41%	104.67%
Interest Expense	-$43.80K	-$55.94K	-$184.4K
YoY Change	20.43%
% of Operating Profit
Other Income/Expense, Net	-$43.80K		-$184.4K
YoY Change	5.71%
Pretax Income	-$747.9K	-$1.208M	-$3.527M
YoY Change	-45.53%	151.03%	115.96%
Income Tax
% Of Pretax Income
Net Earnings	-$747.9K	-$1.208M	-$3.527M
YoY Change	-45.53%	151.03%	115.96%
Net Earnings / Revenue	-40426.49%	-50121.99%	-30904.37%
Basic Earnings Per Share	$0.00		-$0.01
Diluted Earnings Per Share	$0.00	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	404.2M	404.0M shares	392.6M
Diluted Shares Outstanding	404.1M		392.6M

Balance Sheet

Concept	2023 Q2	2023 Q1	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.78K	$13.77K	$13.77K
YoY Change	558.52%	42.84%	42.84%
Cash & Equivalents	$17.78K	$13.77K
Short-Term Investments
Other Short-Term Assets	$10.93K	$18.49K	$18.49K
YoY Change	-86.0%
Inventory	$420.00	$979.00	$980.00
Prepaid Expenses	$10.93K	$18.49K
Receivables	$2.010K	$1.460K	$1.460K
Other Receivables	$19.86K	$0.00	$0.00
Total Short-Term Assets	$50.99K	$34.71K	$34.71K
YoY Change	424.05%	260.01%	260.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$215.4K	$1.547K	$1.550K
YoY Change	35204.92%	111.92%	112.33%
Goodwill	$583.5K	$583.5K
YoY Change	-0.02%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$798.8K	$585.0K	$585.0K
YoY Change	130857.38%
TOTAL ASSETS
Total Short-Term Assets	$50.99K	$34.71K	$34.71K
Total Long-Term Assets	$798.8K	$585.0K	$585.0K
Total Assets	$849.8K	$619.7K	$619.7K
YoY Change	8118.86%	6328.8%	6328.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$564.8K	$390.8K	$451.8K
YoY Change	249.02%	13.15%
Accrued Expenses	$72.91K		$0.00
YoY Change	349.51%		-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$1.055M	$887.8K	$887.8K
YoY Change	69.75%	338.46%	338.46%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.173M	$1.719M	$1.719M
YoY Change	222.18%	357.99%	358.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$2.220K	$2.220K
YoY Change
Other Long-Term Liabilities	$141.1K		$0.00
YoY Change
Total Long-Term Liabilities	$141.1K	$2.224K	$2.220K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.173M	$1.719M	$1.719M
Total Long-Term Liabilities	$141.1K	$2.224K	$2.220K
Total Liabilities	$2.314M	$1.722M	$1.722M
YoY Change	243.1%	358.59%	358.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$6.823M	-$6.076M
YoY Change	93.61%	247.49%
Common Stock	$40.41K	$40.40K
YoY Change	6.32%	8.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.464M	-$1.102M	-$1.102M
YoY Change
Total Liabilities & Shareholders Equity	$849.8K	$619.7K	$619.7K
YoY Change	8118.86%	6328.8%	6328.84%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2023
OPERATING ACTIVITIES
Net Income	-$747.9K	-$1.208M	-$3.527M
YoY Change	-45.53%	151.03%	115.96%
Depreciation, Depletion And Amortization	$190.00	$200.00	$776.00
YoY Change	0.0%
Cash From Operating Activities	-$136.5K	-$56.80K	-$817.8K
YoY Change	-66.27%	-60.64%	165.49%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$2.320K
YoY Change	-100.0%
Acquisitions	$0.00		$6.087K
YoY Change	-100.0%
Other Investing Activities		-$6.090K	-$6.090K
YoY Change
Cash From Investing Activities	$0.00	-$6.090K	-$8.410K
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	140.5K	73.50K	830.3K
YoY Change	-64.67%	-52.26%	161.38%
NET CHANGE
Cash From Operating Activities	-136.5K	-56.80K	-817.8K
Cash From Investing Activities	0.000	-6.090K	-8.410K
Cash From Financing Activities	140.5K	73.50K	830.3K
Net Change In Cash	4.000K	10.61K	4.131K
YoY Change	-156.9%	10.06%	-57.15%
FREE CASH FLOW
Cash From Operating Activities	-$136.5K	-$56.80K	-$817.8K
Capital Expenditures	$0.00	$0.00	$2.320K
Free Cash Flow	-$136.5K	-$56.80K	-$820.1K
YoY Change	-66.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001852707
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	OH
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-02-28
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--02-28
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-56262
CY2023	dei	Entity Registrant Name EntityRegistrantName	BETTER FOR YOU WELLNESS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2903933
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1349 East Broad Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Columbus
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	43205
CY2023	dei	City Area Code CityAreaCode	1 (614)
CY2023	dei	Local Phone Number LocalPhoneNumber	368-9898
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022Q3	dei	Entity Public Float EntityPublicFloat	11740000
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	404214987
CY2023	dei	Auditor Firm AuditorFirmId	1808
CY2023	dei	Auditor Name AuditorName	GBQ Partners LLC
CY2023	dei	Auditor Location AuditorLocation	Columbus, Ohio
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13773
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9642
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1460
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18493
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0
CY2023Q1	us-gaap	Inventory Net InventoryNet	979
CY2022Q1	us-gaap	Inventory Net InventoryNet	0
CY2023Q1	us-gaap	Assets Current AssetsCurrent	34705
CY2022Q1	us-gaap	Assets Current AssetsCurrent	9642
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1547
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0
CY2023Q1	us-gaap	Goodwill Goodwill	583484
CY2022Q1	us-gaap	Goodwill Goodwill	0
CY2023Q1	us-gaap	Assets Assets	619736
CY2022Q1	us-gaap	Assets Assets	9642
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	391553
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	375408
CY2023Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	379759
CY2022Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	0
CY2023Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	293000
CY2022Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	60243
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	0
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	594804
CY2022Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1719359
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	375408
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	2103
CY2022Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	0
CY2023Q1	bfyw	Notes Payable Shopifys Capital NotesPayableShopifysCapital	121
CY2022Q1	bfyw	Notes Payable Shopifys Capital NotesPayableShopifysCapital	0
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2224
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0
CY2023Q1	us-gaap	Liabilities Liabilities	1721583
CY2022Q1	us-gaap	Liabilities Liabilities	375408
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	700000
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	700000
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	700000
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	700000
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	70
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	70
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	404014987
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	404014987
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	370747042
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	370747042
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	40403
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	37075
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4933281
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2395265
CY2023Q1	bfyw	Shares Cancelable SharesCancelable	0
CY2022Q1	bfyw	Shares Cancelable SharesCancelable	-250000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6075601
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2548176
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1101847
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-365766
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	619736
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9642
CY2023	bfyw	Merchandise Sales Amount MerchandiseSalesAmount	11414
CY2022	bfyw	Merchandise Sales Amount MerchandiseSalesAmount	1517
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18409
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	733
CY2023	us-gaap	Gross Profit GrossProfit	-6995
CY2022	us-gaap	Gross Profit GrossProfit	784
CY2023	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	2121213
CY2022	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	2066035
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1214828
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	477990
CY2023	us-gaap	Operating Expenses OperatingExpenses	3336041
CY2022	us-gaap	Operating Expenses OperatingExpenses	2544025
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-3343036
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2543241
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	184389
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	0
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-184389
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3527425
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2543241
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	392643105
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	392643105
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	332388619
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	332388619
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-3750
CY2022	bfyw	Preferred Shares Issued After Reorganization PreferredSharesIssuedAfterReorganization	70000
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	554243
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	68000
CY2022	bfyw	Adjustment To Additional Paid In Capital Shareholder Subscription AdjustmentToAdditionalPaidInCapitalShareholderSubscription	40248
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1441793
CY2022	bfyw	Adjustment To Additional Paid In Capital Expenses Incurred On Behalf Of Company Contributed To Capital AdjustmentToAdditionalPaidInCapitalExpensesIncurredOnBehalfOfCompanyContributedToCapital	6941
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2543241
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-365766
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3750
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	834121
CY2023	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	550000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1241373
CY2023	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	30702
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	49686
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	64212
CY2023	bfyw	Common Shares Issued For Debt Settlement For Purchase Of Subsititary No Subsidiary Acquired This CommonSharesIssuedForDebtSettlementForPurchaseOfSubsititaryNoSubsidiaryAcquiredThis	17500
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3527425
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1101847
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3527425
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2543241
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2121213
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2066035
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	72478
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	51667
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	776
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1460
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-12127
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15422
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	169184
CY2023	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-60243
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0
CY2023	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	379759
CY2022	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2555
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-817755
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-308022
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	6087
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2023	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	2323
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8410
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	56640
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	558000
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2023	us-gaap	Proceeds From Subordinated Short Term Debt ProceedsFromSubordinatedShortTermDebt	275500
CY2022	us-gaap	Proceeds From Subordinated Short Term Debt ProceedsFromSubordinatedShortTermDebt	202475
CY2023	bfyw	Common Stock Issued For Acquisition CommonStockIssuedForAcquisition	-3750
CY2022	bfyw	Common Stock Issued For Acquisition CommonStockIssuedForAcquisition	-108248
CY2023	bfyw	Expenses Contributed To Capital ExpensesContributedToCapital	49686
CY2022	bfyw	Expenses Contributed To Capital ExpensesContributedToCapital	6941
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	830296
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	317664
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	4131
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9642
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9642
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13773
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9642
CY2023	bfyw	Common Stock Issued For Acquisition Value CommonStockIssuedForAcquisitionValue	550000
CY2023	us-gaap	Stock Issued1 StockIssued1	17500
CY2023	bfyw	Discount On Notes Payable For Warrants DiscountOnNotesPayableForWarrants	30702
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	25197
CY2022Q3	bfyw	Warrantcoverageraisedpercentage Warrantcoverageraisedpercentage	0.49
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none; text-indent: 0px; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none; text-indent: 0px; line-height: 12pt;"><div style="white-space: pre-wrap; font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; text-indent: 0px; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; text-indent: 0px; line-height: 12pt;"><div style="white-space: pre-wrap; font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> </div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; text-indent: 0px; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">On an ongoing basis, the Company evaluates its estimates, including those related to the bad debt allowance, sales returns, fair values of financial instruments, equity investments, stock-based compensation<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> goodwill, useful lives of property and equipment, income taxes, and contingent liabilities, among others. The Company bases its estimates on assumptions, both historical and forward looking, that are believed to be reasonable, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities.</div></div>
CY2023Q1	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	13773
CY2022Q1	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	9642
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; text-indent: 0px; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risks</div></div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; text-indent: 0px; line-height: 12pt;"><div style="white-space: pre-wrap; font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> </div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; text-indent: 0px; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">Financial instruments that potentially subject the Company to significant concentration of credit risk primarily consist of cash, cash <div style="display:inline;">equivalents</div>, and accounts receivable. As of February 28, 2023 and 2022, the Company’s cash were held by financial institutions that management believes have acceptable credit. Accounts receivable are typically unsecured. The risk with respect to accounts receivable is mitigated by regular credit evaluations that the Company performs on its distribution partners and its ongoing monitoring of outstanding balances.</div><div style="white-space:pre-line; font-family: "Times New Roman", "serif"; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"/></div>
CY2022	bfyw	Revaluation Of Stock Options Expense Of Grant Date Value RevaluationOfStockOptionsExpenseOfGrantDateValue	34010
CY2022Q2	bfyw	Revaluation Of Stock Options Expense Of Grant Date Value RevaluationOfStockOptionsExpenseOfGrantDateValue	84263
CY2022Q1	us-gaap	Inventory Net InventoryNet	0
CY2023Q1	us-gaap	Inventory Net InventoryNet	979
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	19037
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	43232
CY2022Q3	bfyw	Revaluation Of Stock Options Expense Of Grant Date Value RevaluationOfStockOptionsExpenseOfGrantDateValue	10219
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0
CY2023Q1	bfyw	Stock Based Compensation StockBasedCompensation	2121213
CY2022Q1	bfyw	Stock Based Compensation StockBasedCompensation	2066035
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="border: none; text-align: justify; margin-top: 0px; margin-bottom: 0px; font-family: "Times New Roman", serif; font-size: 10pt; margin-right: 0px; line-height: 12pt; background: none;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; color: rgb(0, 0, 0); line-height: 12pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of Prior Year Presentation </div></div></div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; line-height: 12pt;;text-indent: 0px;"><div style="white-space: pre-wrap; font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> </div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; line-height: 12pt;;text-indent: 0px;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operation.</div></div>
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	265946
CY2021Q4	bfyw	Revaluation Of Stock Options Expense Of Grant Date Value RevaluationOfStockOptionsExpenseOfGrantDateValue	660226
CY2022Q4	bfyw	Revaluation Of Stock Options Expense Of Grant Date Value RevaluationOfStockOptionsExpenseOfGrantDateValue	120631
CY2022	bfyw	Merchandise Sales Amount MerchandiseSalesAmount	1517
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	733
CY2022	us-gaap	Gross Profit GrossProfit	784
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	477990
CY2022	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	2066035
CY2022	us-gaap	Operating Expenses OperatingExpenses	2544025
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2543241
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	332388619
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	332388619
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2543241
CY2022	bfyw	Common Stock Issued CommonStockIssued	2066035
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	169184
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-308022
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	68000
CY2022	bfyw	Subscription Payable SubscriptionPayable	40248
CY2022	bfyw	Expenses Contributed To Capital ExpensesContributedToCapital	6941
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	202475
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	317664
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9642
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9642
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	70
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	37075
CY2022Q1	bfyw	Shares Cancelable SharesCancelable	-250000
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2395265
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2548176
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-365766
CY2023Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3527425
CY2023Q1	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	750759
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	750759
CY2022Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	534081
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	750759
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	534081
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q1	bfyw	Federal Income Tax Rate FederalIncomeTaxRate	0.21
CY2022Q1	bfyw	Federal Income Tax Rate FederalIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.21
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q2	bfyw	Fair Market Value FairMarketValue	550000
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	913
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	12995
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	13908
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	2365
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt	2454
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	537
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	36
CY2022Q4	bfyw	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Notes Payable Gushy BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayableGushy	35000
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	40392
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	-26484
CY2022Q4	us-gaap	Business Acquisitions Purchase Price Allocation Subsequent Years Remaining Adjustments BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments	-557000
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	-583484
CY2023	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	557000
CY2023	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	583484
CY2023	us-gaap	Revenues Net Of Interest Expense RevenuesNetOfInterestExpense	11414
CY2022	us-gaap	Revenues Net Of Interest Expense RevenuesNetOfInterestExpense	67120
CY2023	bfyw	Business Acquisitions Net Income Loss BusinessAcquisitionsNetIncomeLoss	-3527425
CY2022	bfyw	Business Acquisitions Net Income Loss BusinessAcquisitionsNetIncomeLoss	-2592829
CY2023	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0
CY2022	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.03
CY2023	bfyw	Disclosure In Entirety Of Convertible Note DisclosureInEntiretyOfConvertibleNote	<div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; line-height: 12pt;;text-indent: 0px;"><div style="white-space: pre-wrap; font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> </div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; line-height: 12pt;;text-indent: 0px;"><div style="background: none; font-family: "Times New Roman", "serif"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"><div style="font-weight:bold;display:inline;">Note 8 - Convertible Note Payable</div></div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; line-height: 12pt;;text-indent: 0px;"><div style="white-space: pre-wrap; font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> </div></div><div style="null;text-indent: 0px;;text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt; vertical-align: top; width: 8pt; font-size: 10pt; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; line-height: 12pt;"/></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt; vertical-align: top; width: 18pt; font-size: 10pt; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">(A)</div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt; vertical-align: top; font-size: 10pt; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; line-height: 12pt;"><div style="background: none; font-family: "Times New Roman", "serif"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the "Note"). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, and interest of 12% per year and mature on April 12, 2023 (the "Maturity Date"). The Note is convertible into shares of the Company's common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven <div style="letter-spacing: 0px; top: 0px;;display:inline;">(7</div>) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.</div></div></td></tr></table></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin: 0px 0px 0px 0.36in; text-align: justify; background: none; line-height: 12pt;;text-indent: 0px;"><div style="white-space: pre-wrap; font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> </div></div><div style="null;text-indent: 0px;;text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt; vertical-align: top; width: 8pt; font-size: 10pt; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; line-height: 12pt;"/></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt; vertical-align: top; width: 18pt; font-size: 10pt; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">(B)</div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt; vertical-align: top; font-size: 10pt; line-height: 12pt;"><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; line-height: 12pt;;text-indent: 0px;"><div style="background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-family: "Times New Roman", "serif"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"/><div style="font-size: 10pt; background: none; font-family: "Times New Roman", serif; color: rgb(0, 0, 0); line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">On June 7, 2022, the Company entered into a second Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”). The first Security Purchase Agreement with Mast Hill Fund, L.P. was entered On April 12, 2022. Pursuant to the June 7, 2022 Security Purchase Agreement, Mast Hill purchased a promissory note, with a principal amount of </div> <div style="background: none; font-family: "Times New Roman", "serif"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> $310,000 for a purchase price of $279,000 </div><div style="font-size: 10pt; background: none; font-family: "Times New Roman", serif; color: rgb(0, 0, 0); line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">(the “Note”).</div><div style="font-size: 10pt; background: none; font-family: "Times New Roman", serif; color: rgb(0, 0, 0); line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> The closing of the Purchase Agreements occurred on June 7, 2022. The Note bears an original issue discount of </div> <div style="background: none; font-family: "Times New Roman", "serif"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> $31,000, each bear interest of 12% per year and mature on June 7, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 </div><div style="font-size: 10pt; background: none; font-family: "Times New Roman", serif; color: rgb(0, 0, 0); line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven</div> <div style="background: none; font-family: "Times New Roman", "serif"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> (7) </div><div style="font-size: 10pt; background: none; font-family: "Times New Roman", serif; color: rgb(0, 0, 0); line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements</div><div style="font-size: 10pt; background: none; font-family: "Times New Roman", serif; color: rgb(0, 0, 0); line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div> <div style="background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-family: "Times New Roman", "serif"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"/></div></td></tr></table></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; line-height: 12pt;;text-indent: 0px;"/><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin: 0px 0px 0px 0.38in; text-align: justify; background: none; line-height: 12pt;;text-indent: 0px;"><div style="background: none; font-family: "Times New Roman", "serif"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.</div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin: 0px 0px 0px 0.38in; text-align: justify; background: none; line-height: 12pt;;text-indent: 0px;"><div style="white-space: pre-wrap; font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> </div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin: 0px 0px 0px 0.38in; text-align: justify; background: none; line-height: 12pt;;text-indent: 0px;"><div style="background: none; font-family: "Times New Roman", "serif"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.</div><div style="background-color: initial; font-size: 10pt; letter-spacing: 0px; white-space:pre-line; top: 0px;;display:inline;"> </div><div style="display:inline;"><div style="display:inline;"/></div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none; line-height: 12pt;;text-indent: 0px;"><div style="white-space: pre-wrap; font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> </div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin: 0px 0px 0px 0.38in; text-align: justify; background: none; line-height: 12pt;;text-indent: 0px;"><div style="background: none; font-family: "Times New Roman", "serif"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;">On July 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 180 calendar days to file the initial Registration Statement and 270 calendar days to have it declared effective. On October 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 until February 9, 2023, and to have the Registration Statement become effective on or before February 9, 2037.</div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin: 0px 0px 0px 0.38in; text-align: justify; background: none; line-height: 12pt;;text-indent: 0px;"><div style="white-space: pre-wrap; font-family: "Times New Roman", "serif"; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"> </div></div><div style="font-family: "Times New Roman", "serif"; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none; line-height: 12pt;;text-indent: 0px;"><div style="background: none; font-family: "Times New Roman", "serif"; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; line-height: 12pt;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">As of February 28, 2023 the balances on both notes were</div> $594,804. </div></div>
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	594804
CY2023Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1460
CY2022Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	0
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1460
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18493
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2323
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	0
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	776
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	0
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1547
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0
CY2023	us-gaap	Depreciation Depreciation	776
CY2022	us-gaap	Depreciation Depreciation	0
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	390830
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	345408
CY2023Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	293000
CY2022Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	370747042
CY2023Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	379759
CY2023	bfyw	Stock Purchase Warrant Liability Description StockPurchaseWarrantLiabilityDescription	On April 18, 2022, we entered into a Standby Equity Commitment Agreement with MacRab LLC, a Florida limited liability company providing us with an option to sell up to $5,000,000 worth of our Common Stock, par value $0.0001, to MacRab LLC, in increments, over the period ending 24 months after the date that the Company’s registration statement is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. Additionally, we issued MacRab LLC a Common Stock purchase warrant for the purchase of 1,785,714 shares of our common stock as a commitment fee in connection with the execution of the Standby Equity Commitment Agreement. We also entered into a Registration Rights Agreement with the Investor requiring the Company to file a registration statement providing for the registration of the Common Stock issuable to MacRab LLC under the Standby Equity Commitment Agreement and their common stock purchase warrant, and the subsequent resale by MacRab LLC of such Common Stock.
CY2022Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	22320
CY2023	bfyw	Non Cancelable Warrants Percentage NonCancelableWarrantsPercentage	0.08
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.20
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	700000
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	700000
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	700000
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	700000
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	404014987
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	404014987
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	370747042
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2528230
CY2022Q2	us-gaap	Significant Purchase Commitment Description SignificantPurchaseCommitmentDescription	On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the "Note"). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, and interest of 12% per year and mature on April 12, 2023 (the "Maturity Date"). The Note is convertible into shares of the Company's common stock at conversion price of $0.037 per share, subject to adjustment as provided therein.
CY2022Q2	us-gaap	Investment Owned Underlying Face Amount At Market Value InvestmentOwnedUnderlyingFaceAmountAtMarketValue	310000
CY2022Q2	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	279000
CY2022Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	31000
CY2022Q2	srt	Interest Bearing Liabilities Average Rate Paid InterestBearingLiabilitiesAverageRatePaid	0.12
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.037
CY2023	bfyw	Purchase Commitment Shares PurchaseCommitmentShares	4960000
CY2022Q3	us-gaap	Capital Units Outstanding CapitalUnitsOutstanding	78.32
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	2686667
CY2022Q4	bfyw	Extension Value ExtensionValue	64211
CY2022Q4	bfyw	Authorized The Issuance Of Common Shares AuthorizedTheIssuanceOfCommonShares	760780
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17500
CY2022Q4	us-gaap	Partners Capital PartnersCapital	17500
CY2022Q4	us-gaap	Shares Issued SharesIssued	1250000
CY2022Q4	bfyw	Consideration Amount ConsiderationAmount	30000
CY2023	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	Aprari Solutions will be paid $25,000 over 12 months for accounting and auditing assistance services, and for fractional CFO services, $30,000 in cash and $10,000 in stock over 12 months.
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	20000000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber	14000000
CY2023	bfyw	Stock Option Description StockOptionDescription	6,000,000 shares vest over the next year
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	25
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4853749
CY2023Q1	us-gaap	Share Price SharePrice	22
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.72
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0101
CY2022Q1	us-gaap	Share Price SharePrice	11
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.63
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0126
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2121213
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2066035
CY2023	bfyw	Total Unamortized Stock Option Expense TotalUnamortizedStockOptionExpense	614613
CY2022	bfyw	Total Unamortized Stock Option Expense TotalUnamortizedStockOptionExpense	2395265
CY2023Q1	us-gaap	Other Additional Capital OtherAdditionalCapital	4933281
CY2023Q1	us-gaap	Goodwill Goodwill	583484
CY2022Q1	us-gaap	Goodwill Goodwill	0
CY2023	bfyw	Consulting Agreement Description ConsultingAgreementDescription	Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month.
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3309
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0
CY2022Q2	us-gaap	Inventory Net InventoryNet	7037
CY2021Q2	us-gaap	Inventory Net InventoryNet	0
CY2022Q2	us-gaap	Deferred Fuel Cost DeferredFuelCost	0
CY2021Q2	us-gaap	Deferred Fuel Cost DeferredFuelCost	0
CY2022Q2	us-gaap	Assets Current AssetsCurrent	10346
CY2021Q2	us-gaap	Assets Current AssetsCurrent	0
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2129
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0
CY2022Q2	us-gaap	Goodwill Goodwill	583586
CY2021Q2	us-gaap	Goodwill Goodwill	0
CY2022Q2	us-gaap	Assets Assets	596061
CY2021Q2	us-gaap	Assets Assets	0
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	161815
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	0
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	0
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1850
CY2022Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	100160
CY2021Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	0
CY2022Q2	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	2288
CY2021Q2	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	0
CY2022Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	35000
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	299263
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	0
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	2335
CY2021Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	0
CY2022Q2	bfyw	Notes Payable Shopifys Capital NotesPayableShopifysCapital	482
CY2021Q2	bfyw	Notes Payable Shopifys Capital NotesPayableShopifysCapital	0
CY2022Q2	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	254369
CY2021Q2	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	0
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	257186
CY2022Q2	us-gaap	Liabilities Liabilities	556449
CY2021Q2	us-gaap	Liabilities Liabilities	1850
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	70
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	70
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	38012
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	36000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3525841
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39067
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3524311
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76986
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	39612
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1850
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	596061
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	0
CY2022Q2	us-gaap	Revenues Revenues	306
CY2021Q2	us-gaap	Revenues Revenues	0
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6069
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0
CY2022Q2	us-gaap	Gross Profit GrossProfit	-5763
CY2021Q2	us-gaap	Gross Profit GrossProfit	0
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	768313
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	0
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	196996
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	72051
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	965309
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	72051
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-971072
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-72051
CY2022Q2	us-gaap	Other Income OtherIncome	0
CY2021Q2	us-gaap	Other Income OtherIncome	0
CY2022Q2	us-gaap	Interest Expense Other InterestExpenseOther	5063
CY2021Q2	us-gaap	Interest Expense Other InterestExpenseOther	0
CY2022Q2	us-gaap	Other Expenses OtherExpenses	0
CY2021Q2	us-gaap	Other Expenses OtherExpenses	0
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5063
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-976135
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-72051
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	363657794
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	363657794
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	140868130
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	140868130
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-976135
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-72051
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	768313
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2022Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12139
CY2021Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0
CY2022Q2	bfyw	Preferred Stocks Issued PreferredStocksIssued	0
CY2021Q2	bfyw	Preferred Stocks Issued PreferredStocksIssued	70000
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	194
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6060
CY2021Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2022Q2	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	0
CY2021Q2	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1900
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-213593
CY2021Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	0
CY2022Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5063
CY2021Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0
CY2022Q2	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	100160
CY2021Q2	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0
CY2022Q2	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-316
CY2021Q2	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-298115
CY2021Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3951
CY2022Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	6087
CY2022Q2	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	2323
CY2021Q2	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8410
CY2021Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
CY2022Q2	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	28320
CY2021Q2	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2022Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	279000
CY2021Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2022Q2	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-174
CY2021Q2	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0
CY2022Q2	bfyw	Expenses Contributed To Capital ExpensesContributedToCapital	49686
CY2021Q2	bfyw	Expenses Contributed To Capital ExpensesContributedToCapital	3951
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	300192
CY2021Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3951
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6333
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	0
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9642
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3309
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0
CY2022Q2	us-gaap	Interest Paid Net InterestPaidNet	0
CY2021Q2	us-gaap	Interest Paid Net InterestPaidNet	0
CY2022Q2	bfyw	Common Stock Issued For Acquisition Value CommonStockIssuedForAcquisitionValue	550000
CY2021Q2	bfyw	Common Stock Issued For Acquisition Value CommonStockIssuedForAcquisitionValue	0
CY2022Q2	us-gaap	Stock Issued1 StockIssued1	17500
CY2021Q2	us-gaap	Stock Issued1 StockIssued1	0
CY2022Q2	bfyw	Discount On Notes Payable For Warrants DiscountOnNotesPayableForWarrants	13514
CY2021Q2	bfyw	Discount On Notes Payable For Warrants DiscountOnNotesPayableForWarrants	0
CY2022Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
CY2021Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2130
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	123
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0
CY2022Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	107068
CY2021Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	0
CY2022Q3	us-gaap	Inventory Net InventoryNet	5198
CY2021Q3	us-gaap	Inventory Net InventoryNet	0
CY2022Q3	us-gaap	Deferred Fuel Cost DeferredFuelCost	0
CY2021Q3	us-gaap	Deferred Fuel Cost DeferredFuelCost	0
CY2022Q3	us-gaap	Assets Current AssetsCurrent	114519
CY2021Q3	us-gaap	Assets Current AssetsCurrent	0
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1935
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0
CY2022Q3	us-gaap	Goodwill Goodwill	583485
CY2021Q3	us-gaap	Goodwill Goodwill	0
CY2022Q3	us-gaap	Assets Assets	699939
CY2021Q3	us-gaap	Assets Assets	0
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	0
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5500
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0
CY2021Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	365
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	257821
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	0
CY2022Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	190320
CY2021Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	0
CY2022Q3	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	1656
CY2021Q3	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	0
CY2022Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	110000
CY2021Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	14
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	559811
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5865
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	2216
CY2021Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	0
CY2022Q3	bfyw	Notes Payable Shopifys Capital NotesPayableShopifysCapital	201
CY2021Q3	bfyw	Notes Payable Shopifys Capital NotesPayableShopifysCapital	0
CY2022Q3	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	543176
CY2021Q3	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	0
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	545593
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0
CY2022Q3	us-gaap	Liabilities Liabilities	1105404
CY2021Q3	us-gaap	Liabilities Liabilities	5865
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	70
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	70
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	38521
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	36005
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3773889
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49052
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4217945
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90992
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-405465
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-5865
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	699939
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	0
	us-gaap	Revenues Revenues	2022
	us-gaap	Revenues Revenues	0
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9558
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0
	us-gaap	Gross Profit GrossProfit	-7536
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	995932
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	77000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	643257
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9057
	us-gaap	Operating Expenses OperatingExpenses	1639189
	us-gaap	Operating Expenses OperatingExpenses	86057
	us-gaap	Operating Income Loss OperatingIncomeLoss	1646725
	us-gaap	Operating Income Loss OperatingIncomeLoss	-86057
	us-gaap	Interest Expense Other InterestExpenseOther	23043
	us-gaap	Interest Expense Other InterestExpenseOther	0
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23043
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0
	us-gaap	Net Income Loss NetIncomeLoss	-1669768
	us-gaap	Net Income Loss NetIncomeLoss	-86057
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	372031446
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	372031446
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	360000680
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	360000680
	us-gaap	Net Income Loss NetIncomeLoss	-1669768
	us-gaap	Net Income Loss NetIncomeLoss	-86057
	us-gaap	Share Based Compensation ShareBasedCompensation	995932
	us-gaap	Share Based Compensation ShareBasedCompensation	77000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	49475
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	388
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7899
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	123
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	107068
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-117587
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1750
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	190320
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-1409
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	23043
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-628898
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7307
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	6087
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	2323
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8410
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	56640
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	558000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	75000
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	365
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3750
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	bfyw	Expenses Contributed To Capital ExpensesContributedToCapital	49686
	bfyw	Expenses Contributed To Capital ExpensesContributedToCapital	6942
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	629796
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7307
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7512
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	0
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9642
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2130
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0
	us-gaap	Interest Paid Net InterestPaidNet	0
	us-gaap	Interest Paid Net InterestPaidNet	0
	bfyw	Common Stock Issued For Acquisition Value CommonStockIssuedForAcquisitionValue	550000
	bfyw	Common Stock Issued For Acquisition Value CommonStockIssuedForAcquisitionValue	0
	us-gaap	Stock Issued1 StockIssued1	17500
	us-gaap	Stock Issued1 StockIssued1	0
	bfyw	Discount On Notes Payable For Warrants DiscountOnNotesPayableForWarrants	30702
	bfyw	Discount On Notes Payable For Warrants DiscountOnNotesPayableForWarrants	0
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
CY2022Q3	us-gaap	Revenues Revenues	1716
CY2021Q3	us-gaap	Revenues Revenues	0
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3489
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0
CY2022Q3	us-gaap	Gross Profit GrossProfit	-1772
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	227619
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	7000
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	446262
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7005
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	673881
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	14005
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-675653
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14005
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther	17980
CY2021Q3	us-gaap	Interest Expense Other InterestExpenseOther	0
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17980
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-693633
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-14005
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	372031446
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	372031446
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	360000680
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	360000680
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3154
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1495
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	108301
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	0
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	23425
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0
CY2022Q4	us-gaap	Inventory Net InventoryNet	1657
CY2021Q4	us-gaap	Inventory Net InventoryNet	0
CY2022Q4	us-gaap	Deferred Fuel Cost DeferredFuelCost	0
CY2021Q4	us-gaap	Deferred Fuel Cost DeferredFuelCost	0
CY2022Q4	us-gaap	Assets Current AssetsCurrent	138032
CY2021Q4	us-gaap	Assets Current AssetsCurrent	0
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1741
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0
CY2022Q4	us-gaap	Goodwill Goodwill	583484
CY2021Q4	us-gaap	Goodwill Goodwill	0
CY2022Q4	us-gaap	Assets Assets	723257
CY2021Q4	us-gaap	Assets Assets	0
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	156756
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	0
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	117017
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	311541
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	0
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	284499
CY2021Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	0
CY2022Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	895
CY2021Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	0
CY2022Q4	bfyw	Revenue Payable RevenuePayable	128
CY2021Q4	bfyw	Revenue Payable RevenuePayable	0
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	414
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	202000
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	799477
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	273773
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2216
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0
CY2022Q4	bfyw	Notes Payable Shopifys Capital NotesPayableShopifysCapital	166
CY2021Q4	bfyw	Notes Payable Shopifys Capital NotesPayableShopifysCapital	0
CY2022Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	599111
CY2021Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	0
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	601493
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0
CY2022Q4	us-gaap	Liabilities Liabilities	1400970
CY2021Q4	us-gaap	Liabilities Liabilities	273773
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	70
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	70
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	39001
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	36302
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4271508
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1507169
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4988292
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1817314
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-677713
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-273773
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	723257
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	0
	us-gaap	Revenues Revenues	9008
	us-gaap	Revenues Revenues	0
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15381
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0
	us-gaap	Gross Profit GrossProfit	-6373
	us-gaap	Gross Profit GrossProfit	0
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	1453106
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	1535415
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	852184
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	276964
	us-gaap	Operating Expenses OperatingExpenses	2305290
	us-gaap	Operating Expenses OperatingExpenses	1812379
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2311663
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1812379
	us-gaap	Interest Expense Other InterestExpenseOther	128453
	us-gaap	Interest Expense Other InterestExpenseOther	0
	us-gaap	Other Expenses OtherExpenses	0
	us-gaap	Other Expenses OtherExpenses	0
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-128453
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0
	us-gaap	Net Income Loss NetIncomeLoss	-2440116
	us-gaap	Net Income Loss NetIncomeLoss	-1812379
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	372031446
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	372031446
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	287241405
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	287241405
	us-gaap	Net Income Loss NetIncomeLoss	-2440116
	us-gaap	Net Income Loss NetIncomeLoss	-1812379
	us-gaap	Share Based Compensation ShareBasedCompensation	1453106
	us-gaap	Share Based Compensation ShareBasedCompensation	1535415
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	86810
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	582
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1495
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	108301
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-23588
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	0
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-11440
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-63866
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	113267
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	41643
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	284499
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	4412
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	0
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	156756
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-754874
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6941
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	6087
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	2323
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8410
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	56640
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	558000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	202000
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3750
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	bfyw	Expenses Contributed To Capital ExpensesContributedToCapital	49686
	bfyw	Expenses Contributed To Capital ExpensesContributedToCapital	6941
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	756796
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6941
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6488
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	0
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9642
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3154
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0
	bfyw	Common Stock Issued For Acquisition Value CommonStockIssuedForAcquisitionValue	550000
	bfyw	Common Stock Issued For Acquisition Value CommonStockIssuedForAcquisitionValue	0
	us-gaap	Stock Issued1 StockIssued1	17500
	us-gaap	Stock Issued1 StockIssued1	0
	bfyw	Discount On Notes Payable For Warrants DiscountOnNotesPayableForWarrants	30702
	bfyw	Discount On Notes Payable For Warrants DiscountOnNotesPayableForWarrants	0
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0
CY2022Q4	us-gaap	Revenues Revenues	6986
CY2021Q4	us-gaap	Revenues Revenues	0
CY2022Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5823
CY2021Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0
CY2022Q4	us-gaap	Gross Profit GrossProfit	1163
CY2021Q4	us-gaap	Gross Profit GrossProfit	0
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	457174
CY2021Q4	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	1458415
CY2022Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	258401
CY2021Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	267908
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	715575
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	1726323
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-714412
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1726323
CY2022Q4	us-gaap	Interest Expense Other InterestExpenseOther	55935
CY2021Q4	us-gaap	Interest Expense Other InterestExpenseOther	0
CY2022Q4	us-gaap	Other Expenses OtherExpenses	0
CY2021Q4	us-gaap	Other Expenses OtherExpenses	0
CY2022Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-55935
CY2021Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-770347
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-1726323
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	372031446
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	372031446
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	361664351
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	361664351

Files In Submission

Name	View Source	Status
0001575872-23-000924-index-headers.html	Edgar Link	pending
0001575872-23-000924-index.html	Edgar Link	pending
0001575872-23-000924.txt	Edgar Link	pending
0001575872-23-000924-xbrl.zip	Edgar Link	pending
bf003_ex21-1.htm	Edgar Link	pending
bf003_ex31-1.htm	Edgar Link	pending
bf003_ex31-2.htm	Edgar Link	pending
bf003_ex32.htm	Edgar Link	pending
bfyw-20230228.htm	Edgar Link	pending
bfyw-20230228.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
bfyw-20230228_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bfyw-20230228_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bfyw-20230228_cal.xml	Edgar Link	unprocessable
bfyw-20230228_pre.xml	Edgar Link	unprocessable
bfyw-20230228_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BFYW
Better For You Wellness, Inc. Stock $bfyw

2023 Q2 Form 10-K Financial Statement

#000157587223000924 Filed on June 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFYW Better For You Wellness, Inc. Stock $bfyw

2023 Q2 Form 10-K Financial Statement

#000157587223000924 Filed on June 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFYW
Better For You Wellness, Inc. Stock $bfyw